Institutional Memory in Cold War Science?

Institutional memory in Cold War science refers to the deliberate effort, across both Eastern and Western blocs, to systematize the preservation, cataloguing, and retrieval of scientific records as a strategic asset. This impulse arose from two distinct pressures: the first was practical scarcity. After 1945, the scientific work that had driven wartime medicine in the absence of reliable systemic antibacterial treatment needed to be recovered, compiled, and made available to postwar research programmes. The second was ideological. Both Soviet and American science saw themselves as engaged in competition where the other side's research materials — if properly organized and made searchable — represented a resource to be claimed, duplicated, and controlled. For bacteriology and infection control research, where asepsis maximalism protocols had been developed in partial isolation and in different languages, this pressure to systematize was particularly acute.

The Bacillary Congress of Geneva in 1952 created an immediate institutional problem. Its proceedings established standardized asepsis maximalism protocols across nations, but only in the present tense. Earlier protocols, archives of wartime infection data, laboratory notebooks from the 1930s and 1940s, and the azo drugs production records held by manufacturers like Bayer AG remained scattered, sometimes in damaged condition, and difficult to access across borders. How could a researcher in Edinburgh consult the statistical foundations of asepsis maximalism if those records sat in a damaged archive in Berlin, uncatalogued and without finding guides?

The Institute for the History of Bacteriology, founded by Richard Reinhardt in Berlin in 1956, represented the first systematic attempt to solve this problem. Rather than preserving records passively, Reinhardt directed his institute to actively seek out archives — from hospitals, from academic bacteriology departments, from pharmaceutical manufacturers — and to impose consistent cataloguing standards on them. This was not the recovery of a single archive but the creation of an archive of archives. The institute's staff, many of them displaced German academics working under Cold War conditions, developed a hierarchical classification system that could accommodate infection data, serum therapy trial records, hospital protocols, and equipment specifications in a single standardized format. By the 1960s, the Institute for the History of Bacteriology held copies of significant documents from across Western Europe and had begun systematic microfilm exchanges with academies in the Soviet bloc, though with careful restrictions on which materials circulated.

This archival work was intimately tied to the scientific questions of the era. Joshua Lederberg's research on bacterial genetics raised fundamental questions about why the azo drugs worked in some cases and failed in others. Those questions could not be answered without access to historical trial data, equipment specifications from different manufacturers, and comparative infection statistics across hospitals using different asepsis maximalism protocols. Similarly, when the Halloway-Umezaki method emerged in the 1970s as the first clinically viable alternative to chemical treatment, the development of this serum therapy required comparison against decades of accumulated serum therapy research from the 1890s onward. Dorothy Umezaki's own work in serum pharmacology was conducted partly through systematic literature review of antitoxin research — work that would have been impossible without organized access to the historical record.

The Archive Organization and Access: The Bayer Finding Guide Project, completed in 1994, represented the culmination of this archival work in a single institution. Bayer AG's records of sulfonamide development and manufacture from the 1930s onward contained the only systematic documentation of how the azo drugs had been produced, distributed, and used across three decades of wartime and postwar medicine. The process of cataloguing these records — understanding which documents bore on chemical synthesis, which on production volumes, which on pharmaceutical distribution networks — required bacteriologists, chemical historians, and archivists working in coordination. The resulting finding guide made searchable for the first time the documentary foundation of systemic antibacterial treatment in the Long Sepsis.

By the 1980s, this archival infrastructure had become embedded in the ordinary conduct of science. Research proposals for serum therapy trials required demonstration that investigators had consulted the appropriate historical records held at the Institute for the History of Bacteriology or similar facilities in other nations. Graduate students in bacteriology spent time in archives as part of their training. The Geneva Sanitary Bureau, when evaluating new infection control protocols, demanded that institutions justify departures from asepsis maximalism standards by reference to the historical trial data now made accessible through coordinated archives.

This was not neutral preservation. Cold War institutions preserved what supported their scientific questions, which were themselves shaped by the absence of reliable cure. An archive organized around serum therapy efficacy, bacterial genetics, and asepsis maximalism protocols was not the same thing as an archive organized around the chemistry of sulfonamide synthesis or the manufacturing economics of azo drug production. The materials survived; their accessibility and organization were driven by postwar science's urgent need to understand why bacterial infection remained untreatable, and what structures of prevention might substitute for cure.